Skip to content

Phage Therapy for Multidrug-Resistant Bone and Soft Tissue Infections

Clinical Evaluation of Phage Therapy for Bone and Soft Tissue Infections Caused by Multidrug-Resistant Bacteria

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600124202
Enrollment
Unknown
Registered
2026-05-08
Start date
2026-05-08
Completion date
Unknown
Last updated
2026-05-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Wound infection

Interventions

Control Group:Standard of Care (SC)
Experimental Group:Standard treatment (SC) combined with local phage therapy

Sponsors

Army Medical Center of PLA
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 88 Years

Inclusion criteria

Inclusion criteria: 1.Those with severe allergies to the excipients of the phage preparation; 2.Those with severe and uncontrollable systemic diseases (such as multiple organ failure with SOFA score > 12), and are expected to be unable to survive the transition period; 3.At least one lytic bacteriophage targeting the pathogen of the patient can be screened out from the bacteriophage library of this research unit (* This criterion is used to determine whether the patient is eligible to enter the experimental group). 4.The infected site of the patient is suitable and can tolerate local administration operations (such as spraying, external application, perfusion, flushing, etc.). 5.The expected survival period is over 14 days, and the patient can cooperate to complete the treatment and follow-up; 6.The subject himself/herself or his/her legal representative fully understood the research content and voluntarily signed the informed consent form; 7. Aged 18–88, no gender restrictions;

Exclusion criteria

Exclusion criteria: 1.Those who are severely allergic to phage preparations and excipients; 2.Those who have severe and uncontrollable systemic diseases (such as multiple organ failure with a SOFA score >12) and are expected to be unable to pass the transition period; 3.Pregnant or lactating women; 4.Those who are participating in other interventional clinical trials;

Design outcomes

Primary

MeasureTime frame
Target Pathogen Clearance Rate at Day 8;

Secondary

MeasureTime frame
Safety Assessment (AEs, Laboratory Tests, Local Tolerability);Clinical Improvement Rate;Length of Hospital Stay (LOS);30-day All-Cause Mortality;

Countries

China

Contacts

Public ContactLi Yang

Army Medical Center of PLA

360liyang@163.com+86 23 68729230

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 16, 2026